Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series

Erica Brivio; Christophe F. Chantrain; Tanja A. Gruber; Adriana Thano; Fanny Rialland; Audrey Contet; Sarah Elitzur; Luciano Dalla-Pozza; Krisztián Miklós Kállay; Chi kong Li; Motohiro Kato; Inna Markova; Kjeld Schmiegelow; Nicole Bodmer; Erin H. Breese; Raoull Hoogendijk; Rob Pieters; Christian Michel Zwaan

doi:10.1111/bjh.17333

Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series

Erica Brivio, Christophe F. Chantrain, Tanja A. Gruber, Adriana Thano, Fanny Rialland, Audrey Contet, Sarah Elitzur, Luciano Dalla-Pozza, Krisztián Miklós Kállay, Chi kong Li, Motohiro Kato, Inna Markova, Kjeld Schmiegelow, Nicole Bodmer, Erin H. Breese, Raoull Hoogendijk, Rob Pieters, Christian Michel Zwaan

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

18 Citaten (Scopus)

Samenvatting

No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22⁺ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m² (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.

Originele taal-2	Engels
Pagina's (van-tot)	1172-1177
Aantal pagina's	6
Tijdschrift	British Journal of Haematology
Volume	193
Nummer van het tijdschrift	6
DOI's	https://doi.org/10.1111/bjh.17333
Status	Gepubliceerd - jun. 2021

Toegang tot document

10.1111/bjh.17333

Citeer dit

Brivio, E., Chantrain, C. F., Gruber, T. A., Thano, A., Rialland, F., Contet, A., Elitzur, S., Dalla-Pozza, L., Kállay, K. M., Li, C. K., Kato, M., Markova, I., Schmiegelow, K., Bodmer, N., Breese, E. H., Hoogendijk, R., Pieters, R., & Zwaan, C. M. (2021). Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series. British Journal of Haematology, 193(6), 1172-1177. https://doi.org/10.1111/bjh.17333

@article{bdd096dc6191404dbc3d2ef1d8607b12,

title = "Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series",

abstract = "No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.",

keywords = "ALL, infants, inotuzumab ozogamicin",

author = "Erica Brivio and Chantrain, {Christophe F.} and Gruber, {Tanja A.} and Adriana Thano and Fanny Rialland and Audrey Contet and Sarah Elitzur and Luciano Dalla-Pozza and K{\'a}llay, {Kriszti{\'a}n Mikl{\'o}s} and Li, {Chi kong} and Motohiro Kato and Inna Markova and Kjeld Schmiegelow and Nicole Bodmer and Breese, {Erin H.} and Raoull Hoogendijk and Rob Pieters and Zwaan, {Christian Michel}",

note = "Publisher Copyright: {\textcopyright} 2021 British Society for Haematology and John Wiley & Sons Ltd.",

year = "2021",

month = jun,

doi = "10.1111/bjh.17333",

language = "English",

volume = "193",

pages = "1172--1177",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

Brivio, E, Chantrain, CF, Gruber, TA, Thano, A, Rialland, F, Contet, A, Elitzur, S, Dalla-Pozza, L, Kállay, KM, Li, CK, Kato, M, Markova, I, Schmiegelow, K, Bodmer, N, Breese, EH, Hoogendijk, R , Pieters, R & Zwaan, CM 2021, 'Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series', British Journal of Haematology, vol. 193, nr. 6, blz. 1172-1177. https://doi.org/10.1111/bjh.17333

TY - JOUR

T1 - Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia

T2 - a case series

AU - Brivio, Erica

AU - Chantrain, Christophe F.

AU - Gruber, Tanja A.

AU - Thano, Adriana

AU - Rialland, Fanny

AU - Contet, Audrey

AU - Elitzur, Sarah

AU - Dalla-Pozza, Luciano

AU - Kállay, Krisztián Miklós

AU - Li, Chi kong

AU - Kato, Motohiro

AU - Markova, Inna

AU - Schmiegelow, Kjeld

AU - Bodmer, Nicole

AU - Breese, Erin H.

AU - Hoogendijk, Raoull

AU - Pieters, Rob

AU - Zwaan, Christian Michel

PY - 2021/6

Y1 - 2021/6

N2 - No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.

AB - No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.

KW - ALL

KW - infants

KW - inotuzumab ozogamicin

UR - http://www.scopus.com/inward/record.url?scp=85100188201&partnerID=8YFLogxK

U2 - 10.1111/bjh.17333

DO - 10.1111/bjh.17333

M3 - Article

C2 - 33529389

AN - SCOPUS:85100188201

SN - 0007-1048

VL - 193

SP - 1172

EP - 1177

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 6

ER -

Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit